Alpha Cubed Investments’s BioAtla BCAB Stock Holding History

Alpha Cubed Investments’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-823	Closed	-$16.3K	–	300
2025 Q2	$16.3K	Buy	+823	New	+$16.7K	﹤0.01%	295

Other funds holding BCAB

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Alpha Cubed Investments's BCAB Position: Q3 2025 in Review

Alpha Cubed Investments sold out of BioAtla (BCAB) in Q3 2025, closing a stake of 823 shares — an estimated $16.3K sold.

Alpha Cubed Investments first reported a position in BCAB in Q2 2025 and held it in 1 quarter. The position peaked at $16.3K in Q2 2025. 43 funds tracked by Wall St. Rank hold BCAB as of Q3 2025.

Alpha Cubed Investments reported no remaining BioAtla position as of Q3 2025 after selling out during the quarter.
Alpha Cubed Investments sold 823 BioAtla shares in Q3 2025, an estimated $16.3K.
Alpha Cubed Investments first reported a position in BioAtla in Q2 2025 and held it in 1 quarter.
Alpha Cubed Investments's BioAtla position peaked at $16.3K in Q2 2025.
43 funds tracked by Wall St. Rank held BioAtla as of Q3 2025.

Based on Alpha Cubed Investments's 13F filing for Q3 2025, filed 3 Nov 2025.